

---

# Atypical Breast Proliferative Lesions and Benign Breast Disease

---

Farin Amersi • Kristine Calhoun  
Editors

# Atypical Breast Proliferative Lesions and Benign Breast Disease

 Springer

*Editors*

Farin Amersi  
Samuel Oschin Comprehensive Cancer Inst  
Cedars-Sinai Medical Center  
Los Angeles, CA  
USA

Kristine Calhoun  
School of Medicine  
University of Washington School  
of Medicine  
Seattle, WA  
USA

ISBN 978-3-319-92656-8      ISBN 978-3-319-92657-5 (eBook)  
<https://doi.org/10.1007/978-3-319-92657-5>

Library of Congress Control Number: 2018955294

© Springer International Publishing AG, part of Springer Nature 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

---

## Preface

The management of atypical breast lesions continues to evolve and become more complex. The days of surgical excision for any atypical lesion have been replaced by more nuanced decision making and individualized patient management. There is considerable controversy as to whether entities such as papillomas, radial scars, fibroepithelial lesions, pseudoangiomatous stromal hyperplasia (PASH), flat epithelial atypia (FEA), atypical ductal and lobular hyperplasia (ADH and ALH), lobular carcinoma in situ (LCIS), and ductal carcinoma in situ (DCIS) represent risk factors for future breast cancer or whether they are instead obligate precursor lesions that will themselves transform into malignancy. A better understanding of the prognostic and therapeutic implications of each of these lesions once diagnosed is important for assessing subsequent individual breast cancer risk. Risk assessment tools are available for screening high risk patients, and understanding the utility and limitations of these tools is important for all clinicians involved in the care of breast patients.

There have been significant advances in breast cancer screening in the last several years, including the addition of breast tomosynthesis to 2D mammogram, automated breast ultrasound, molecular imaging, as well as accelerated breast MRI protocols. This has led us to question whether women at risk for breast cancer need additional breast cancer screening using these newer imaging modalities or if standard mammography plus or minus MRI is sufficient. In addition, with these advances in imaging, many wonder if women with atypical proliferative lesions once diagnosed on pathologic analysis can be observed rather than proceed on to surgical excision. The role of observation, surgical excision, and even prophylactic mastectomy in women with atypical proliferative lesions continues to be debated; however, there is data that can guide physicians in the management of these complex patients.

Although sharing the terminology of in situ lesions, LCIS and DCIS are currently managed quite differently. LCIS in general is deemed a risk lesion, although a variant, pleomorphic lobular carcinoma in situ (PLCIS) is a distinct pathological entity within LCIS often managed much more like DCIS, despite limited natural history data and no clear consensus regarding surgical margins or the need for adjuvant treatment to prevent recurrence. Recently, ductal carcinoma in situ (DCIS) has been the subject of much controversy regarding whether it is truly a cancer or is instead best described as a precursor lesion. The traditional management of DCIS with surgery (lumpectomy and radiation versus mastectomy) is now being debated

and recent data demonstrates that low-grade DCIS can be managed in nontraditional ways. Clinical trials are actively accruing patients with low- and intermediate-grade DCIS to observation and close surveillance instead of surgical excision. Finally, new guidelines for chemoprevention, as well as new agents in addition to traditional tamoxifen and raloxifen for women with atypical proliferative lesions, LCIS, PLCIS, and DCIS, are available and should be discussed as an option when guiding management of these patients.

The goal of this book is to provide a comprehensive review of atypical breast proliferative lesions and their management complexities. We hope it will serve as a valuable resource for nurse practitioners, physician assistants, breast and surgical oncology fellows, genetics counselors, geneticists, as well as other clinicians and surgeons who are referred and manage these complex breast patients. All chapters have been written by experts in the field who have research and clinical interest in each of these disease entities, and we the editors thank them for their willingness to contribute to an aspect of breast care that is less robustly discussed than malignancy. We hope that you learn much from their input and appreciate the opportunity to contribute to the growing information regarding atypical breast proliferative lesions. Thank you and enjoy.

Los Angeles, CA, USA  
Seattle, WA, USA

Farin Amersi  
Kristine Calhoun

---

# Contents

<b>1</b>	<b>The Spectrum of Risk Lesions in Breast Pathology: Risk Factors or Cancer Precursors? . . . . .</b>	<b>1</b>
	Kimberly Allison and Kelly Mooney	
<b>2</b>	<b>Lobular Carcinoma In Situ: Risk Factor or Cancer Precursor? . . . . .</b>	<b>21</b>
	Kevin M. Sullivan, Meghan R. Flanagan, Mark R. Kilgore, and Benjamin O. Anderson	
<b>3</b>	<b>Ductal Carcinoma In Situ: Risk Factor or Cancer . . . . .</b>	<b>37</b>
	Nicci Owusu-Brackett and Funda Meric-Bernstam	
<b>4</b>	<b>Diagnostic Management of Papillomas, Radial Scars, and Flat Epithelial Atypia: Core Biopsy Alone Versus Core Biopsy Plus Excision . . . . .</b>	<b>51</b>
	George Z. Li, Beth T. Harrison, and Faina Nakhlis	
<b>5</b>	<b>Diagnostic Management of Fibroepithelial Lesions: When Is Excision Indicated? . . . . .</b>	<b>63</b>
	Nicholas Manguso and Catherine Dang	
<b>6</b>	<b>Diagnostic Management of the Atypical Hyperplasias: Core Biopsy Alone Versus Excisional Biopsy . . . . .</b>	<b>79</b>
	Emily Siegel and Alice Chung	
<b>7</b>	<b>Diagnostic Management of LCIS: Core Biopsy Alone Versus Core Biopsy plus Excision for Classic Versus Pleomorphic LCIS . . . . .</b>	<b>89</b>
	Batul Al-zubeidy and Nora Hansen	
<b>8</b>	<b>Breast Cancer Risk Prediction in Women with Atypical Breast Lesions . . . . .</b>	<b>103</b>
	Suzanne B. Coopey and Kevin S. Hughes	
<b>9</b>	<b>Advanced Screening Options and Surveillance in Women with Atypical Breast Lesions . . . . .</b>	<b>115</b>
	Erin Crane, Nicole Sondel Lewis, Erini Makariou, Janice Jeon, Judy Song, and Charlotte Dillis	

---

<b>10</b>	<b>The Role of Chemoprevention in the Prevention of Breast Cancer</b> . . . . .	129
	Jinny Gunn, E. Alexa Elder, and Sarah McLaughlin	
<b>11</b>	<b>Prophylactic Mastectomy in Patients with Atypical Breast Lesions</b> . . . . .	147
	Judy C. Boughey and Amy C. Degnim	
<b>12</b>	<b>The Nonsurgical Management of Ductal Carcinoma In Situ (DCIS)</b> . . . . .	159
	Alastair M. Thompson	
<b>13</b>	<b>Surgical Treatment of Ductal Carcinoma In Situ</b> . . . . .	171
	Meghan R. Flanagan and Kimberly J. Van Zee	
	<b>Index</b> . . . . .	193

---

## Contributors

**E. Alexa Elder, MD** Department of Surgery, Mayo Clinic, Jacksonville, FL, USA

**Kimberly Allison, MD** Department of Pathology, Stanford University, School of Medicine, Palo Alto, CA, USA

**Batul Al-zubeidy, MD** Lynn Sage Comprehensive Breast Center, Chicago, IL, USA

**Benjamin O. Anderson, MD** Department of Surgery, University of Washington, Seattle, WA, USA

Departments of Surgery and Global Health, University of Washington, Seattle, WA, USA

Surgery and Global Health Medicine, University of Washington, Seattle, WA, USA

**Judy C. Boughey, MD** Department of Surgery, Mayo Clinic, Rochester, MN, USA

**Alice Chung, MD** Cedars-Sinai Medical Center, Los Angeles, CA, USA

**Suzanne B. Coopey, MD** Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

**Erin Crane, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

**Catherine Dang, MD** Cedars-Sinai Medical Center, Department of Surgery, Los Angeles, CA, USA

**Amy C. Degnim, MD, FACS** Department of Surgery, Mayo Clinic, Rochester, MN, USA

**Charlotte Dillis, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

**Meghan R. Flanagan, MD, MPH** Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Jinny Gunn, MD** Department of Surgery, Mayo Clinic, Jacksonville, FL, USA

**Nora Hansen, MD** Lynn Sage Comprehensive Breast Center, Chicago, IL, USA



**Beth T. Harrison, MD** Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA

**Kevin S. Hughes, MD** Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

**Janice Jeon, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

**Mark R. Kilgore, MD, FASCP, FCAP** Department of Pathology, University of Washington, Seattle, WA, USA

**Nicole Sondel Lewis, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

**George Z. Li, MD** Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA

**Erini Makariou, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

**Nicholas Manguso, MD** Cedars-Sinai Medical Center, Department of Surgery, Los Angeles, CA, USA

**Sarah McLaughlin, MD** Department of Surgery, Mayo Clinic, Jacksonville, FL, USA

Section of Surgical Oncology, Jacksonville, FL, USA

**Funda Meric-Bernstam, MD** Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Kelly Mooney, MD** Department of Pathology, Stanford University, School of Medicine, Palo Alto, CA, USA

**Faina Nakhlis** Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA

**Nicci Owusu-Brackett, MD** Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Emily Siegel, MD** Cedars-Sinai Medical Center, Los Angeles, CA, USA

**Judy Song, MD** Department of Radiology, Medstar Georgetown University Hospital, Washington, DC, USA

---

**Kevin M. Sullivan, MD** Department of Surgery, University of Washington, Seattle, WA, USA

**Alastair M. Thompson, ALCM, BSc, MBChB, MD, FRCSEd** Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Kimberly J. Van Zee, MS, MD** Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA